Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
Recent Articles
RELATED ARTICLES
-
Health Guard plans dual listing to fund HPV vaccine fight
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
-
FAST NEWS: Luzhu Biotech repurchases shares
2480.HK
- Payment app Lianlian seeks IPO relief from cash crunch
-
Akeso marks profit milestone with swift rights issue
9926.HK
